1. Efficacy, safety and albuminuria‐reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12‐week, double‐blind randomized study (the GUARD Study). Issue 4 (17th February 2017) Authors: Yoon, Sun A.; Han, Byoung G.; Kim, Sung G.; Han, Sang Y.; Jo, Young I.; Jeong, Kyung H.; Oh, Kook H.; Park, Hyeong C.; Park, Sun H.; Kang, Shin W.; Na, Ki R.; Kang, Sun W.; Kim, Nam H.; Jang, Young H.; Shin, Seong H.; Cha, Dae R. Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 4(2017) Page Start: 590 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗